Antibody drug conjugate: the “biological missile” for targeted cancer therapy Article Open access 22 March 2022 Homogeneous multi-payload antibody–drug conjugates Article 17 May 2024 References Joubert, N., Beck, A., Dumontet, C. & Denevault-Sabourin, C. Antibody–drug conjugates: the la...
The antibody, linker, and drug should be properly designed or selected to achieve the desired efficacy while minimizing off-target toxicity. With a unique and complex structure, there is inherent heterogeneity introduced by product-related variations and the manufacturing process. Her...
the antibody–siRNA conjugates (ARC) have emerged as a potential vehicle for targeted siRNA drug delivery, with the ability to overcome the current obstacles in siRNA delivery. In this review, we summarized the efforts in the development of antibody–siRNA conjugates and hope to provide a basic ...
A comprehensive review of key factors affecting the efficacy of antibody drug conjugate AnupamaSamantasinghar, ...Kyung HyunChoi, inBiomedicine & Pharmacotherapy, 2023 1Introduction Antibody Drug Conjugate(ADC) is an emerging class of potent biological drugs that combine a highly potent cytotoxic ...
Antibody–drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs) covalently attached to a cytotoxic drug via a chemical linker. It combines both the advantages of highly specific targeting ability and highly potent killing effect to a
Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review. JAMA Oncol. 2021 Dec 1;7(12):1873-1881. doi:10.1001/jamaoncol.2021.3595. Zhang L, Ma Y, Zhao Y, et al. BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in ...
抗体偶联药物(antibody-drug conjugate,ADC)热度不减,全球范围内的交易、合作、许可授权频发。宏观来看,全球处于活跃状态的ADC药物已达499款,13款药物获批上市,临床活跃药物125款。2021年,新增30款ADC进入人体首次试验(first-in-human trial,FIH)、3款药物获批上市,都是ADC领域的最高记录。2022年,ADC药物发展依旧迅猛...
点击上方的 行舟Drug ▲ 添加关注 抗体偶联药物(Antibody-Drug Conjugate,ADC)是由靶向特异性抗原的抗体或抗体片段与有效载荷(payload)通过连接子(linker)偶联而成的一类创新型抗体药物。与传统抗体药物相比,ADC产品兼具传统小分子药物强效作用及抗体药物的靶向性,以降低全身毒性并更有选择性地将有效载荷递送至肿瘤细胞...
In this phase I study, the safety, pharmacokinetics, and antitumour activity of the HER2-targeted antibody–drug conjugate A166 were evaluated in patients with HER2-expressing advanced solid tumours. Patients with advanced solid tumours refractory to standard therapies received A166 at doses of 0.1...
EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates 2023, Translational Lung Cancer Research Antibody-drug Conjugate Targets, Drugs, and Linkers 2022, Current Cancer Drug Targets ...